XML 98 R35.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2020
Proceeds from Issuance of Common Stock $ 493,481 $ 2,338,349      
Purchase Obligation 3,800,000       $ 1,600,000
Subscription Agreement [Member]          
Accounts payable and accrued expenses $ 0       $ 0
Pilaris Laboratories LLC [Member]          
Agreement term       10 years  
Percentage of net income       10.00%  
Option expiration period     10 years    
Pilaris Laboratories LLC [Member] | CVLBPR [Member]          
Agreements of performance fees, description       As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products.  
MALPHABET LLC [Member]          
Agreements of performance fees, description     The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts were earned or owed as of September 30, 2021.    
Options granted     20,000    
Exercise price     $ 2.50    
MALPHABET LLC [Member] | Common Stock One [Member]          
Options granted     20,000    
Exercise price     $ 2.50    
Proceeds from Issuance of Common Stock     $ 7,500,000    
MALPHABET LLC [Member] | Common Stock Two [Member]          
Options granted     20,000    
Exercise price     $ 2.50    
Proceeds from Issuance of Common Stock     $ 10,000,000    
MALPHABET LLC [Member] | Common Stock Three [Member]          
Options granted     40,000    
Exercise price     $ 3.75    
Proceeds from Issuance of Common Stock     $ 20,000,000